Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Analyze both dividend and price returns yearly to evaluate total performance and income potential from index fund investments.
28,655 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
A new AI-driven forecast puts Solana on a trajectory to smash expectations by late 2026, driven by on-chain adoption ...
Oil prices drop to a three-month low following news of a Trump Iran framework, signaling potential relief for inflati...
XRP sits near the $1 level, slipping 9% over the past week and 52% year over year. An analyst says the move could for...
Velvet has surged 1,700% in a single month, driving it into crypto headlines. Traders weigh whether momentum will sus...
Cal-Maine Foods is navigating a turning point: a fading egg-price super-cycle and a strategic push into specialty egg...
Solana surged 13% last week, its strongest performance of 2026, driven by ETF demand and higher futures activity. Tra...
A surge of XRP tokens—roughly 472 million coins worth about $650 million—was sent to Binance, heightening bets on nea...
XRP trades in a narrowing range near critical levels as traders await a breakout. The ripple price analysis: next pha...
A key on-chain signal points to a potential drop toward $700 for ethereum (eth), even as network activity grows and i...
A Federal Reserve study finds remote employees have quietly earned a wage edge over their in-office counterparts, wit...
Qualcomm and Micron lead another leg higher in the AI semiconductor rally, as data center demand and memory tightness...